Skip to main content
Have a personal or library account? Click to login
Multiobjective optimization of fluphenazine nanocomposite formulation using NSGA-II method Cover

Multiobjective optimization of fluphenazine nanocomposite formulation using NSGA-II method

Open Access
|Mar 2022

Figures & Tables

Fig. 1

Methodology flow chart. NPs, nanoparticles

Fig. 2

NPs fabrication process flow chart. CS, chitosan; DSC, differential scanning calorimetry; FTIR, Fourier-transform infrared spectroscopy; FZN, fluphenazine; NPs, nanoparticles; TPP, tripolyphosphate; XRD, X-ray diffraction

Fig. 3

Simples design plot. CS, chitosan; FZN, fluphenazine; TPP, tripolyphosphate

Fig. 4

NSGA-II process – adapted from Acampora et al. [46]. NSGA-II, non-dominated sorting genetic algorithm

Table 1

Screening DoE model with experimental values

RunsIndependent variablesResponses
(A)(B)(C)(X1)(X2)Size (nm)ZP (mV)LE (%)
Run 11562.522.56.0182527.997.6
Run 21522.562.56.032194.096.8
Run 3522.572.56.0183244.494.0
Run 4572.522.54.0315224.085.8
Run 51562.522.56.032588.097.4
Run 6522.572.56.033894.394.2
Run 71522.562.56.0181974.597.0
Run 8572.522.56.032797.292.6
Run 91562.522.54.0314824.191.2
Run 101562.522.54.01815921.291.1
Run 11522.572.54.0185496.983.4
Run 121522.562.54.036427.684.6
Run 13572.522.54.01815028.084.0
Run 14572.522.56.0182797.992.7
Run 15522.572.54.033026.883.3
Run 161522.562.54.0186317.684.8

[i] Note: (A): FZN%, (B): CS%, (C): TPP%, (X1): pH, and (X2): mixing time.

[ii] CS, chitosan; FZN, fluphenazine; LE, loading efficiency; TPP, tripolyphosphate; ZP, zeta potential.

Table 2

ANOVA for size-screening study

SourceDFSeq SSAdj SSAdj MSF-valueP-value
Regression1165411864654118645946533901.350.000
Component only
Linear21685201225941727129708631966.060.000
Quadratic11056393410563934105639341601.230.000
A × B11056393410563934105639341601.230.000
Component × X1
Linear32662232434654360115514531750.920.000
A × X111641309619779395197793952998.070.000
B × X119152068955902955902144.890.000
C × X11105715936090453609045547.040.000
Quadratic11136088411360884113608841722.030.000
A × B × X111136088411360884113608841722.030.000
Component × X2
Linear365111261942060.640.629
A × X2152010879108791.650.268
B × X211446170117010.260.638
C × X21454510744107441.630.271
Quadratic16200620062000.940.387
A × B × X216200620062000.940.387
Residual Error426390263906597
Total1565438254

[i] Note: (A): FZN%, (B): CS%, (C): TPP%, (X1): pH, and (X2): mixing time.

[ii] ANOVA, analysis of variance; CS, chitosan; FZN, fluphenazine; TPP, tripolyphosphate.

Table 3

ANOVA for ZP-screening study

SourceDFSeq SSAdj SSAdj MSF-valueP-value
Regression111008.681008.6891.69877.300.000
Component only
Linear2426.63256.25128.124108.010.000
Quadratic10.230.230.2310.190.682
A × B10.230.230.2310.190.682
Component × X1
Linear3573.36152.8250.94042.940.002
A × X11282.000.290.2880.240.648
B × X11284.68109.49109.48892.300.001
C × X116.685.155.1474.340.106
Quadratic10.610.610.6060.510.514
A × B × X110.610.610.6060.510.514
Component × X2
Linear34.007.662.5532.150.236
A × X210.080.910.9140.770.430
B × X212.846.676.6715.620.077
C × X211.080.670.6710.570.494
Quadratic13.843.843.8423.240.146
A × B × X213.843.843.8423.240.146
Residual Error44.744.741.186
Total151013.42

[i] Note: (A): FZN%, (B): CS%, (C): TPP%, (X1): pH, and (X2): mixing time.

[ii] ANOVA, analysis of variance; CS, chitosan; FZN, fluphenazine; TPP, tripolyphosphate; ZP, zeta potential.

Table 4

ANOVA for LE-screening study

SourceDFSeq SSAdj SSAdj MSF-valueP-value
Regression11448.552448.55240.7774172.150.000
Component Only
Linear268.18610.7915.395422.780.007
Quadratic114.81114.81114.811362.530.001
A × B114.81114.81114.811362.530.001
Component × X1
Linear3361.159190.17763.3923267.620.000
A × X11274.9114.7264.726319.950.011
B × X117.77910.48910.489344.280.003
C × X1178.46818.42518.424677.780.001
Quadratic13.6293.6293.628815.320.017
A × B × X113.6293.6293.628815.320.017
Component × X2
Linear30.6940.7330.24421.030.469
A × X210.0010.0000.00000.000.995
B × X210.6810.4930.49292.080.223
C × X210.0130.0180.01770.070.798
Quadratic10.0730.0730.07320.310.608
A × B × X210.0730.0730.07320.310.608
Residual Error40.9480.9480.2369
Total15449.499

[i] Note: (A): FZN%, (B): CS%, (C): TPP%, (X1): pH, and (X2): mixing time.

[ii] ANOVA, analysis of variance; CS, chitosan; FZN, fluphenazine; LE, loading efficiency; TPP, tripolyphosphate.

Table 5

Complete DoE study-data

Run codesNon-dependent variablesResponses
(FZN)(CS)(TPP)(pH)SizeZPLE
F01-15.072.5022.506.0225782
F01-25.072.5022.506.0221781
F01-35.072.5022.506.0221881
F02-112.553.7533.754.02531480
F02-212.553.7533.754.02621680
F02-312.553.7533.754.02571679
F03-110.045.0045.006.0255587
F03-210.045.0045.006.0262590
F03-310.045.0045.006.0259690
F04-115.042.5042.504.06261283
F04-215.042.5042.504.06251082
F04-315.042.5042.504.06271282
F05-17.533.7558.754.0687780
F05-27.533.7558.754.0686981
F05-37.533.7558.754.0670979
F06-15.047.5047.506.0209584
F06-25.047.5047.506.0203588
F06-35.047.5047.506.0217583
F07-115.022.5062.504.0499970
F07-215.022.5062.504.0514770
F07-315.022.5062.504.0502969
F08-17.533.7558.756.0297488
F08-27.533.7558.756.0307487
F08-37.533.7558.756.0317487
F09-110.045.0045.004.05011682
F09-210.045.0045.004.05061683
F09-310.045.0045.004.05041681
F10-17.558.7533.756.0164687
F10-27.558.7533.756.0179686
F10-37.558.7533.756.0164686
F11-112.553.7533.756.0299691
F11-212.553.7533.756.0296691
F11-312.553.7533.756.0297691
F12-115.062.5022.506.0228891
F12-215.062.5022.506.0221891
F12-315.062.5022.506.0230892
F13-15.022.5072.506.0276484
F13-25.022.5072.506.0264484
F13-35.022.5072.506.0272484
F14-112.533.7553.756.0226591
F14-212.533.7553.756.0225591
F14-312.533.7553.756.0225691
F15-17.558.7533.754.03601674
F15-27.558.7533.754.03601674
F15-37.558.7533.754.03601974
F16-110.022.5067.506.0277489
F16-210.022.5067.506.0265590
F16-310.022.5067.506.0267490
F17-110.067.5022.504.01952088
F17-210.067.5022.504.01902288
F17-310.067.5022.504.01912388
F18-15.072.5022.504.01671682
F18-25.072.5022.504.01682282
F18-35.072.5022.504.01642282
F19-110.022.5067.504.0353783
F19-210.022.5067.504.0351783
F19-310.022.5067.504.0351783
F20-15.022.5072.504.0428779
F20-25.022.5072.504.0433879
F20-35.022.5072.504.0427779
F21-115.022.5062.506.0458596
F21-215.022.5062.506.0438596
F21-315.022.5062.506.0447596
F22-15.047.5047.504.04141180
F22-25.047.5047.504.04041280
F22-35.047.5047.504.04241680
F23-110.067.5022.506.0239789
F23-210.067.5022.506.0237789
F23-310.067.5022.506.0240889
F24-115.062.5022.504.01851891
F24-215.062.5022.504.01812091
F24-315.062.5022.504.01832091
F25-112.533.7553.754.05281082
F25-212.533.7553.754.05111282
F25-312.533.7553.754.05071482
F26-115.042.5042.506.0232692
F26-215.042.5042.506.0230692
F26-315.042.5042.506.0230692

[i] Note: Run codes can be read as follows: F (Run number-replicate number). For example, F03-2 means the 2nd replicate in the 3rd run.

[ii] CS, chitosan; FZN, fluphenazine; LE, loading efficiency; TPP, tripolyphosphate; ZP, zeta potential.

Fig. 5

Main effect plots. LE, loading efficiency; NPs, nanoparticles

Fig. 6

Contour plots. CS, chitosan; LE, loading efficiency; NPs, nanoparticles; TPP, tripolyphosphate; ZP, zeta potential

Table 6

Regression model evaluations

ModelR-seq (%)R-seq (adj) (%)R-seq (pred) (%)
Model (1): size96.2395.2494.12
Model (2): ZP96.0595.0993.79
Model (3): IE94.4492.9891.61

[i] ZP, zeta potential.

Fig. 7

Analysis of residuals. LE, loading efficiency; NPs, nanoparticles; ZP, zeta potential

Table 7

Pareto solutions

Solution no.SizeZPLE
S1215.621.588.8
S2204.121.489.4
S3198.021.389.6
S4191.921.289.8
S5183.220.889.5
S6171.220.790.4
S7167.220.690.7
S8165.320.590.6
S9153.020.291.1
S10147.920.091.2
S11145.519.991.3
S12143.219.891.3
S13141.019.791.4
S14138.419.591.3
S15136.519.291.1
S16132.719.091.2
S17129.418.991.4
S18127.218.891.6
S19126.618.791.6
S20164.64.991.7
S21164.64.991.7
S22165.15.091.7
S23168.95.191.7
S24177.15.291.7
S25173.64.991.8
S26177.95.191.8
S27177.25.091.9
S28177.25.091.9
S29184.35.291.8
S30186.15.391.8
S31190.75.491.7
S32181.45.191.9
S33189.15.391.9
S34192.75.491.8
S35195.55.591.8
S36199.95.691.7
S37189.85.192.0
S38194.25.491.9
S39200.45.691.8
S40194.45.292.0
S41194.55.392.0
S42200.75.691.9
S43203.75.791.8
S44201.85.292.1
S45205.45.791.9
S46214.86.091.7
S47207.35.392.1
S48205.65.692.0
S49208.85.891.9
S50211.35.592.1
S51216.96.091.9
S52217.26.191.9
S53220.86.291.8
S54221.95.592.2
S55217.05.992.0
S56217.86.092.0
S57221.56.291.9
S58223.76.391.8
S59225.96.491.8
S60230.76.591.7
S61223.26.092.1
S62223.66.192.0
S63227.26.491.9
S64231.86.691.8
S65234.86.791.8
S66238.96.891.7

[i] LE, loading efficiency; ZP, zeta potential.

Table 8

Validation experiments – data

Run codesNPs input fabrication parametersSize (nm)ZP (mV)LE (%)
ABCX−1Experimental ValuesPredicted using Eq. (5)ExperimentalPredicted using Eq. (6)Experimental ValuesPredicted using Eq. (7)
V1131.020.493.0
V2130.021.391.3
V3128.220.092.6
V413.3%64.2%22.5%4.0125.4126.619.018.791.491.6%
V5129.022.092.0
V6132.020.093.1
V7125.417.792.5
V8126.018.090.4
V9127.018.492.5
Mean128.2126.619.618.792.191.6
Standard Deviation2.451.480.90
Test of hypothesisH0: μ = 126.6H0: μ =18.7H0: μ = 91.6
H1: μ ≠ 126.6H1: μ ≠ 18.7H1: μ ≠ 91.6
P-valueP-value = 0.082P-value = 0.092P-value = 0.140
95% CI for μ(126.3–130.1 nm)(18.5 – 20.8 mV)(91.4–92.8%)

[i] CI, confidence interval; LE, loading efficiency; NPs, nanoparticles; ZP, zeta potential.

Fig. 8

DSC Thermograms. (A) Drug free (FZN). (B) Blank (CSNPs). (C) Nanocomposite (FZNCSNPs). DSC, differential scanning calorimetry; FZN, fluphenazine

Fig. 9

In-vitro drug release study

Fig. 10

XRD-diffractograms. (A) Drug free (FZN). (B) Blank (CSNPs). (C) Nanocomposite (FZNCSNPs). (D) Physical Mixture of FZN with CSNPs. FZN, fluphenazine; XRD, X-ray diffraction

Fig. 11

Chemical Interactions between the CSNPs and FZN drug. (A) FZN chemical structure. (B) CS chemical structure. (C) TPP chemical structure. CS, chitosan; FZN, fluphenazine; TPP, tripolyphosphate

Fig. 12

FTIR spectrums. (A) Drug free (FZN). (B) Blank (CSNPs). (C) Nanocomposite (FZNCSNPs). FTIR, Fourier-transform infrared spectroscopy; FZN, fluphenazine

DOI: https://doi.org/10.2478/msp-2021-0042 | Journal eISSN: 2083-134X (formerly 2083-124X) | Journal ISSN: 2083-1331
Language: English
Page range: 517 - 544
Submitted on: Dec 2, 2021
Accepted on: Jan 26, 2022
Published on: Mar 27, 2022
Published by: Wroclaw University of Science and Technology
In partnership with: Paradigm Publishing Services

© 2022 Ahmed Adnan Abu Sharar, Saleem Z. Ramadan, Samer Hasan Hussein-Al-Ali, published by Wroclaw University of Science and Technology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.